Veterinary Medicines

Buscopan Compositum ad us.vet. 4 mg/ml + 500 mg/ml, solution injectable pour chevaux, veaux et chiens

Authorised
  • Hyoscine butylbromide
  • Metamizole sodium
Download as PDF

Product identification

Medicine name:
Buscopan Compositum ad us.vet. 4 mg/ml + 500 mg/ml, solution injectable pour chevaux, veaux et chiens
Buscopan Compositum ad us. vet. 4 mg/ml + 500 mg/ml, Injektionslösung für Pferde, Kälber und Hunde
Active substance:
  • Hyoscine butylbromide
  • Metamizole sodium
Target species:
  • Cattle
  • Cattle (calf)
  • Horse
  • Dog
Route of administration:
  • Intravenous use
  • Subcutaneous use

Product details

Active substance and strength:
  • Hyoscine butylbromide
    4.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Metamizole sodium
    500.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Intravenous use
    • Cattle
      • Milk
        no withdrawal period
    • Cattle (calf)
      • Meat and offal
        15
        day
    • Horse
      • Meat and offal
        12
        day
      • Milk
        no withdrawal period
    • Dog
  • Subcutaneous use
    • Cattle
      • Milk
        no withdrawal period
    • Cattle (calf)
      • Meat and offal
        15
        day
    • Horse
      • Meat and offal
        12
        day
      • Milk
        no withdrawal period
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QA03BB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Buscopan Compositum ad us. vet 1 Vial of 100 ml with Solution for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Labiana Life Sciences S.A.
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • V 642/97/11/0345
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."